000087679 001__ 87679
000087679 005__ 20200716101420.0
000087679 0247_ $$2doi$$a10.1093/jac/dkz007
000087679 0248_ $$2sideral$$a111592
000087679 037__ $$aART-2019-111592
000087679 041__ $$aeng
000087679 100__ $$aRequena, S.
000087679 245__ $$aClinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
000087679 260__ $$c2019
000087679 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087679 5203_ $$aBackground: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2.
Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed.
Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
000087679 536__ $$9info:eu-repo/grantAgreement/EC/FP7/223131/EU/Collaborative HIV and Anti-HIV Drug Resistance Network/CHAIN
000087679 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000087679 590__ $$a5.439$$b2019
000087679 592__ $$a2.23$$b2019
000087679 591__ $$aINFECTIOUS DISEASES$$b10 / 93 = 0.108$$c2019$$dQ1$$eT1
000087679 593__ $$aInfectious Diseases$$c2019$$dQ1
000087679 591__ $$aPHARMACOLOGY & PHARMACY$$b22 / 270 = 0.081$$c2019$$dQ1$$eT1
000087679 593__ $$aPharmacology (medical)$$c2019$$dQ1
000087679 591__ $$aMICROBIOLOGY$$b24 / 134 = 0.179$$c2019$$dQ1$$eT1
000087679 593__ $$aPharmacology$$c2019$$dQ1
000087679 593__ $$aMicrobiology (medical)$$c2019$$dQ1
000087679 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000087679 700__ $$aLozano, AB.
000087679 700__ $$aCaballero, E.
000087679 700__ $$aGarcía, F.
000087679 700__ $$aNieto, MC.
000087679 700__ $$aTéllez, R.
000087679 700__ $$aFernández, JM.
000087679 700__ $$aTrigo, M.
000087679 700__ $$aRodríguez-Avial, I.
000087679 700__ $$aMartín-Carbonero, L.
000087679 700__ $$aMiralles, P.
000087679 700__ $$aSoriano, V.
000087679 700__ $$ade, Mendoza, C.
000087679 700__ $$aHIV-2 Spanish Study Group
000087679 700__ $$aRodríguez, C.
000087679 700__ $$aVera, M.
000087679 700__ $$aDel, Romero, J.
000087679 700__ $$aMarcaida, G.
000087679 700__ $$aOcete, MD.
000087679 700__ $$aCaballero, E.
000087679 700__ $$0(orcid)0000-0001-5134-1006$$aAguilera, A.$$uUniversidad de Zaragoza
000087679 700__ $$aBENITO, R.
000087679 700__ $$ade, Lejarazu, RO.
000087679 700__ $$aRojo, S.
000087679 700__ $$aEirós, JM.
000087679 700__ $$aRamos, C.
000087679 700__ $$aGarcía, J.
000087679 700__ $$aPaz, I.
000087679 700__ $$aTrigo, M.
000087679 700__ $$aDiz, J.
000087679 700__ $$aGarcía-Campello, M.
000087679 700__ $$aRodríguez-Iglesias, M.
000087679 700__ $$aHernández-Betancor, A.
000087679 700__ $$aMartín, AM.
000087679 700__ $$aRamos, JM.
000087679 700__ $$aGimeno, A.
000087679 700__ $$aSánchez, V.
000087679 700__ $$aGómez-Hernando, C.
000087679 700__ $$aCilla, G.
000087679 700__ $$aPérez-Trallero, E.
000087679 700__ $$aFernández-Pereira, L.
000087679 700__ $$aNiubó, J.
000087679 700__ $$aHernández, M.
000087679 700__ $$aLópez-Lirola, AM.
000087679 700__ $$aGómez-Sirvent, JL.
000087679 700__ $$aForce, L.
000087679 700__ $$aCabrera, J.
000087679 700__ $$aPérez, S.
000087679 700__ $$aMorano, L.
000087679 700__ $$aRaya, C.
000087679 700__ $$aGonzález-Praetorius, A.
000087679 700__ $$aCifuentes, C.
000087679 700__ $$aPeñaranda, M.
000087679 700__ $$aNieto, MC.
000087679 700__ $$aMontejo, JM.
000087679 700__ $$aRoc, L.
000087679 700__ $$aViciana, I.
000087679 700__ $$aLozano, AB.
000087679 700__ $$aFernández-Fuertes, E.
000087679 700__ $$aFernández, JM.
000087679 700__ $$aGarcía-Bermejo, I.
000087679 700__ $$aGaspar, G.
000087679 700__ $$aTéllez, R.
000087679 700__ $$aGórgolas, M.
000087679 700__ $$aMiralles, P.
000087679 700__ $$aPérez, L.
000087679 700__ $$aValeiro, M.
000087679 700__ $$aAldamiz, T.
000087679 700__ $$aMargall, N.
000087679 700__ $$aSuárez, A.
000087679 700__ $$aRodríguez-Avial, I.
000087679 700__ $$aRequena, S.
000087679 700__ $$aBenítez-Gutiérrez, L.
000087679 700__ $$aCuervas-Mons, V.
000087679 700__ $$ade, Mendoza, C.
000087679 700__ $$aBarreiro, P.
000087679 700__ $$aSoriano, V.
000087679 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000087679 773__ $$g74, 5 (2019), 1357-1372$$pJ. antimicrob. chemother.$$tThe Journal of antimicrobial chemotherapy$$x1460-2091
000087679 8564_ $$s121883$$uhttps://zaguan.unizar.es/record/87679/files/texto_completo.pdf$$yPostprint
000087679 8564_ $$s52269$$uhttps://zaguan.unizar.es/record/87679/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000087679 909CO $$ooai:zaguan.unizar.es:87679$$particulos$$pdriver
000087679 951__ $$a2020-07-16-08:40:17
000087679 980__ $$aARTICLE